Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The DRAFFT-2 trial has completed recruitment and will now begin its follow up phase.

DRAFFT-2

When patients are treated in the operating theatre for a broken wrist, the surgeon will regularly use either a cast or wires to hold the wrist in place. At the moment we don't know whether the cast or wire is better, and whether one is more expensive than the other. DRAFFT-2 is comparing cast and wires to see which treatment is better, by asking patients about their wrist for a year after their injury.

Since early 2017, patients with broken wrists who were admitted to one of 36 participating hospitals in England and Wales have been enrolling in DRAFFT-2, and we have now finished the recruitment part of the study. Thank you to all the patients who are taking part, and well done to clinical and research staff at all the hospitals who have helped with the study!

For the next year we will be asking participants to complete questionnaires to tell us how their wrist is recovering and about any issues they have had along the way. In Summer/Autumn 2020 we will be able to calculate which treatment is better, publish the results in medical journals, and put a summary of the results on our website and in leaflets at participating hospitals.

DRAFFT-2 is funded by the National Institute for Health Research Health Technology Assessment programme (ID: 15/27/01).

Similar stories

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.